As China embraces AI, only 24% of US pharma execs bet on it for drug-making - South China Morning Post

While China is rapidly adopting AI for pharmaceutical development, only a quarter of US pharma executives are betting on the technology. This suggests the US may be falling behind in a critical industry with major implications for drug discovery and healthcare innovation.